Alivus Life Sciences Ltd (ALIVUS) — shareholding pattern, promoter holding, financials and share price
About Alivus Life Sciences Ltd (ALIVUS)
Alivus Life Sciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ALIVUS and on the BSE under scrip code 543322. Its ISIN is INE03Q201024.
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Alivus Life Sciences Limited, formerly Glenmark Life Sciences, specializes in developing, manufacturing, and marketing Active Pharmaceutical Ingredients (APIs) across various therapeutic segments.
The company's Q3 FY26 revenue saw substantial growth of 14.4% QoQ, driven by recovery in the CDMO segment and robust demand in regulated markets such as Europe and Japan.
Listed peers in Pharmaceuticals: Jubilant Pharmova Ltd, Concord Biotech Ltd, Corona Remedies Ltd, Marksans Pharma Ltd, Shilpa Medicare Ltd, Viyash Scientific Ltd.
Valuation & Returns
10 Jul 2026At ₹1,160 a share on 10 Jul 2026, Alivus Life Sciences Ltd (ALIVUS) was valued at a price-to-earnings ratio of 25.22x against an industry P/E of 36.41x and a price-to-book of 5.05x on a book value of ₹229.54 per share as of Mar 2025. Solomo computes return on equity of 20.04% and return on capital employed of 26.33% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 25.22x
- Industry P/E
- 36.41x
- P/B
- 5.05x
- EPS (TTM)
- ₹45.99
- Book value / share
- ₹229.54
- ROE
- 20.04%
- ROCE
- 26.33%
- ROA
- 16.55%
- Debt / equity
- 0.02x
- Dividend yield
- 0.43%
- EBITDA margin
- 32.61%
- 52-week range
- ₹830 – ₹1,193.3
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2021In the year ended Mar 2021, Alivus Life Sciences Ltd (ALIVUS) reported revenue of ₹1,885 crore, net profit of ₹352 crore and earnings per share of ₹358.74. That compares with revenue of ₹1,537 crore and net profit of ₹313 crore in Mar 2020. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹689 crore and net profit ₹163 crore (standalone).
| Metric | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|
| Revenue (₹ cr) | 886 | 1,537 | 1,885 |
| Net profit (₹ cr) | 196 | 313 | 352 |
| EPS (₹) | 997.86 | 1,597.37 | 358.74 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 9.20% | 3.98% | 4.54% |
| Profit growth | 9.18% | 5.07% | 3.13% |
| Stock price CAGR | - | 25% | 9% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 74.87% of Alivus Life Sciences Ltd (ALIVUS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 5.54% and domestic institutional investors (DII) hold 7.18%. Market capitalisation was ₹14,238 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2021.
Largest disclosed public shareholders in Jun 2026: Quant Mutual Fund - Quant Small Cap Fund 2.51%, Government Pension Fund Global 2.4%, Massachusetts Institute of Technology 1.23%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 74.87% | - | 5.54% | 7.18% | 25.13% |
| Mar 2026 | 74.87% | - | 5.29% | 7.28% | 25.13% |
| Dec 2025 | 74.91% | - | 5.09% | 7.12% | 25.09% |
| Sep 2025 | 74.91% | - | 6.84% | 5.47% | 25.09% |
| Jun 2025 | 74.94% | - | 6.42% | 5.61% | 25.06% |
| Mar 2025 | 74.99% | - | 6.57% | 5.19% | 25.01% |
| Dec 2024 | 75% | - | 6.74% | 4.86% | 25% |
| Sep 2024 | 75% | - | 7.85% | 4.16% | 25% |